Skip Navigation
Skip to contents

JPTM : Journal of Pathology and Translational Medicine

OPEN ACCESS
SEARCH
Search

Author index

Page Path
HOME > Articles and issues > Author index
Search
Jang-Hee Kim 4 Articles
Prognostic and predictive markers in glioblastoma and ALK overexpression
Jang-Hee Kim
J Pathol Transl Med. 2021;55(3):236-237.   Published online May 13, 2021
DOI: https://doi.org/10.4132/jptm.2021.04.29
  • 1,976 View
  • 75 Download
  • 2 Citations
PDF

Citations

Citations to this article as recorded by  
  • CAR T-cells to treat brain tumors
    Grace Guzman, Karolina Pellot, Megan R. Reed, Analiz Rodriguez
    Brain Research Bulletin.2023;[Epub]     CrossRef
  • Glioblastoma multiforme targeted delivery of docetaxel using bevacizumab-modified nanostructured lipid carriers impair in vitro cell growth and in vivo tumor progression
    Leonardo Delello Di Filippo, Jonatas Lobato Duarte, Juliana Hofstätter Azambuja, Rubia Isler Mancuso, Marcela Tavares Luiz, Victor Hugo Sousa Araújo, Ingrid Delbone Figueiredo, Lucas Barretto-de-Souza, Rafael Miguel Sábio, Estela Sasso-Cerri, Amanda Marti
    International Journal of Pharmaceutics.2022; 618: 121682.     CrossRef
New insights into classification and risk stratification of encapsulated thyroid tumors with a predominantly papillary architecture
Chan Kwon Jung, So Yeon Park, Jang-Hee Kim, Kennichi Kakudo
J Pathol Transl Med. 2020;54(3):197-203.   Published online May 14, 2020
DOI: https://doi.org/10.4132/jptm.2020.04.29
  • 3,721 View
  • 183 Download
  • 1 Citations
PDF

Citations

Citations to this article as recorded by  
  • Updates in the Pathologic Classification of Thyroid Neoplasms: A Review of the World Health Organization Classification
    Yanhua Bai, Kennichi Kakudo, Chan Kwon Jung
    Endocrinology and Metabolism.2020; 35(4): 696.     CrossRef
A Multi-institutional Study of Prevalence and Clinicopathologic Features of Non-invasive Follicular Thyroid Neoplasm with Papillary-like Nuclear Features (NIFTP) in Korea
Ja Yeong Seo, Ji Hyun Park, Ju Yeon Pyo, Yoon Jin Cha, Chan Kwon Jung, Dong Eun Song, Jeong Ja Kwak, So Yeon Park, Hee Young Na, Jang-Hee Kim, Jae Yeon Seok, Hee Sung Kim, Soon Won Hong
J Pathol Transl Med. 2019;53(6):378-385.   Published online October 21, 2019
DOI: https://doi.org/10.4132/jptm.2019.09.18
  • 5,237 View
  • 299 Download
  • 11 Citations
AbstractAbstract PDF
Background
In the present multi-institutional study, the prevalence and clinicopathologic characteristics of non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) were evaluated among Korean patients who underwent thyroidectomy for papillary thyroid carcinoma (PTC).
Methods
Data from 18,819 patients with PTC from eight university hospitals between January 2012 and February 2018 were retrospectively evaluated. Pathology reports of all PTCs and slides of potential NIFTP cases were reviewed. The strict criterion of no papillae was applied for the diagnosis of NIFTP. Due to assumptions regarding misclassification of NIFTP as non-PTC tumors, the lower boundary of NIFTP prevalence among PTCs was estimated. Mutational analysis for BRAF and three RAS isoforms was performed in 27 randomly selected NIFTP cases.
Results
The prevalence of NIFTP was 1.3% (238/18,819) of all PTCs when the same histologic criteria were applied for NIFTP regardless of the tumor size but decreased to 0.8% (152/18,819) when tumors ≥1 cm in size were included. The mean follow-up was 37.7 months and no patient with NIFTP had evidence of lymph node metastasis, distant metastasis, or disease recurrence during the follow-up period. A difference in prevalence of NIFTP before and after NIFTP introduction was not observed. BRAFV600E mutation was not found in NIFTP. The mutation rate for the three RAS genes was 55.6% (15/27).
Conclusions
The low prevalence and indolent clinical outcome of NIFTP in Korea was confirmed using the largest number of cases to date. The introduction of NIFTP may have a small overall impact in Korean practice.

Citations

Citations to this article as recorded by  
  • Analysis of a pre-2017 follicular variant papillary thyroid carcinoma cohort reclassified as noninvasive follicular thyroid neoplasm with papillary-like features (NIFTP): an 11-year retrospective single institution experience
    Shaham Beg, Sana Irfan Khan, Isabella Cui, Theresa Scognamiglio, Rema Rao
    Journal of the American Society of Cytopathology.2023; 12(2): 112.     CrossRef
  • Noninvasive Follicular Thyroid Neoplasm With Papillary-Like Nuclear Features: What a Surgeon Should Know
    Jabir Alharbi, Thamer Alraddadi, Haneen Sebeih, Mohammad A Alessa, Haddad H Alkaf, Ahmed Bahaj, Sherif K Abdelmonim
    Cureus.2023;[Epub]     CrossRef
  • Clinical-Pathological and Molecular Evaluation of 451 NIFTP Patients from a Single Referral Center
    Paola Vignali, Agnese Proietti, Elisabetta Macerola, Anello Marcello Poma, Liborio Torregrossa, Clara Ugolini, Alessio Basolo, Antonio Matrone, Teresa Rago, Ferruccio Santini, Rossella Elisei, Gabriele Materazzi, Fulvio Basolo
    Cancers.2022; 14(2): 420.     CrossRef
  • Noninvasive follicular thyroid neoplasm with papillary-like nuclear features: its updated diagnostic criteria, preoperative cytologic diagnoses and impact on the risk of malignancy
    Hee Young Na, So Yeon Park
    Journal of Pathology and Translational Medicine.2022; 56(6): 319.     CrossRef
  • SFE-AFCE-SFMN 2022 Consensus on the management of thyroid nodules : Follow-up: How and how long?
    Sophie Leboulleux, Livia Lamartina, Emmanuelle Lecornet Sokol, Fabrice Menegaux, Laurence Leenhardt, Gilles Russ
    Annales d'Endocrinologie.2022; 83(6): 407.     CrossRef
  • Different Threshold of Malignancy for RAS-like Thyroid Tumors Causes Significant Differences in Thyroid Nodule Practice
    Kennichi Kakudo
    Cancers.2022; 14(3): 812.     CrossRef
  • Clinicopathological parameters for predicting non-invasive follicular thyroid neoplasm with papillary features (NIFTP)
    Eunju Jang, Kwangsoon Kim, Chan Kwon Jung, Ja Seong Bae, Jeong Soo Kim
    Therapeutic Advances in Endocrinology and Metabolism.2021; 12: 204201882110005.     CrossRef
  • The Incidence of Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features: A Meta-Analysis Assessing Worldwide Impact of the Reclassification
    Chanchal Rana, Huy Gia Vuong, Thu Quynh Nguyen, Hoang Cong Nguyen, Chan Kwon Jung, Kennichi Kakudo, Andrey Bychkov
    Thyroid.2021;[Epub]     CrossRef
  • The Genomic Landscape of Thyroid Cancer Tumourigenesis and Implications for Immunotherapy
    Amandeep Singh, Jeehoon Ham, Joseph William Po, Navin Niles, Tara Roberts, Cheok Soon Lee
    Cells.2021; 10(5): 1082.     CrossRef
  • Noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) is rare, benign lesion using modified stringent diagnostic criteria: Reclassification and outcome study
    David Cubero Rego, Hwajeong Lee, Anne Boguniewicz, Timothy A. Jennings
    Annals of Diagnostic Pathology.2020; 44: 151439.     CrossRef
  • Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features: From Echography to Genetic Profile
    Francesca Maletta, Enrico Costantino Falco, Alessandro Gambella, Jasna Metovic, Mauro Papotti
    The Tohoku Journal of Experimental Medicine.2020; 252(3): 209.     CrossRef
Evaluation of the VE1 Antibody in Thyroid Cytology Using Ex Vivo Papillary Thyroid Carcinoma Specimens
Yon Hee Kim, Hyunee Yim, Yong-Hee Lee, Jae Ho Han, Kyi Beom Lee, Jeonghun Lee, Euy Young Soh, Seon-Yong Jeong, Jang-Hee Kim
J Pathol Transl Med. 2016;50(1):58-66.   Published online December 14, 2015
DOI: https://doi.org/10.4132/jptm.2015.10.10
  • 8,501 View
  • 70 Download
  • 8 Citations
AbstractAbstract PDF
Background
Recently, VE1, a monoclonal antibody against the BRAFV600E mutant protein, has been investigated in terms of its detection of the BRAFV600E mutation. Although VE1 immunostaining and molecular methods used to assess papillary thyroid carcinoma in surgical specimens are in good agreement, evaluation of VE1 in thyroid cytology samples is rarely performed, and its diagnostic value in cytology has not been well established. In present study, we explored VE1 immunoexpression in cytology samples from ex vivo papillary thyroid carcinoma specimens in order to minimize limitations of low cellularity and sampling/targeting errors originated from thyroid fineneedle aspiration and compared our results with those obtained using the corresponding papillary thyroid carcinoma tissues. Methods: The VE1 antibody was evaluated in 21 cases of thyroid cytology obtained directly from ex vivo thyroid specimens. VE1 immunostaining was performed using liquid-based cytology, and the results were compared with those obtained using the corresponding tissues. Results: Of 21 cases, 19 classic papillary thyroid carcinomas had BRAFV600E mutations, whereas two follicular variants expressed wild-type BRAF. VE1 immunoexpression varied according to specimen type. In detection of the BRAFV600E mutation, VE1 immunostaining of the surgical specimen exhibited 100% sensitivity and 100% specificity, whereas VE1 immunostaining of the cytology specimen exhibited only 94.7% sensitivity and 0% specificity. Conclusions: Our data suggest that VE1 immunostaining of a cytology specimen is less specific than that of a surgical specimen for detection of the BRAFV600E mutation, and that VE1 immunostaining of a cytology specimen should be further evaluated and optimized for clinical use.

Citations

Citations to this article as recorded by  
  • VE1 immunohistochemistry is an adjunct tool for detection of BRAF V600E mutation: Validation in thyroid cancer patients
    Faiza A. Rashid, Sobia Tabassum, Mosin S. Khan, Hifzur R. Ansari, Muhammad Asif, Ahmareen K. Sheikh, Syed Aga
    Journal of Clinical Laboratory Analysis.2021;[Epub]     CrossRef
  • Effective utilization of liquid-based cytology for thyroid lesions
    Yukie YAMAYA
    The Journal of the Japanese Society of Clinical Cytology.2021; 60(3): 164.     CrossRef
  • Diagnostic efficacy of brafv600e immunocytochemistry in thyroid aspirates in bethesda category iv and papillary thyroid carcinoma
    Nidhi Anand, Tushar Agrawal, Anurag Gupta, Saumya Shukla, Roma Pradhan, Nuzhat Husain
    Journal of Cytology.2021; 38(3): 113.     CrossRef
  • The immunocytochemical expression ofVE‐1 (BRAFV600E‐related) antibody identifies the aggressive variants of papillary thyroid carcinoma on liquid‐based cytology
    Patrizia Straccia, Chiara Brunelli, Esther D. Rossi, Paola Lanza, Maurizio Martini, Teresa Musarra, Celestino Pio Lombardi, Alfredo Pontecorvi, Guido Fadda
    Cytopathology.2019; 30(5): 460.     CrossRef
  • Utility of the BRAF p.V600E immunoperoxidase stain in FNA direct smears and cell block preparations from patients with thyroid carcinoma
    Amber L. Smith, Michelle D. Williams, John Stewart, Wei-Lien Wang, Savitri Krishnamurthy, Maria E. Cabanillas, Sinchita Roy-Chowdhuri
    Cancer Cytopathology.2018; 126(6): 406.     CrossRef
  • Refinement of the criteria for ultrastructural peritubular capillary basement membrane multilayering in the diagnosis of chronic active/acute antibody-mediated rejection
    Heounjeong Go, Sung Shin, Young Hoon Kim, Duck Jong Han, Yong Mee Cho
    Transplant International.2017; 30(4): 398.     CrossRef
  • Thyroid Fine-Needle Aspiration Cytology Practice in Korea
    Yoon Jin Cha, Ju Yeon Pyo, SoonWon Hong, Jae Yeon Seok, Kyung-Ju Kim, Jee-Young Han, Jeong Mo Bae, Hyeong Ju Kwon, Yeejeong Kim, Kyueng-Whan Min, Soonae Oak, Sunhee Chang
    Journal of Pathology and Translational Medicine.2017; 51(6): 521.     CrossRef
  • Use of monoclonal antibodies to detect specific mutations in formalin-fixed, paraffin-embedded tissue sections
    Zhenying Guo, Ricardo V. Lloyd
    Human Pathology.2016; 53: 168.     CrossRef

JPTM : Journal of Pathology and Translational Medicine